Abstract 931P
Background
Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) ineligible for curative local therapy typically receive first-line (1L) systemic treatment with platinum-based chemotherapy and pembrolizumab or cetuximab. However, early recurrent patients (<6 months from the last curative local treatment) have been excluded from most 1L systemic treatment studies. Therefore, treatment outcomes for early recurrent patients, the impact of different time-to-recurrence intervals (TTRI), and the influence of recurrence patterns on survival remain unclear.
Methods
We analyzed non-curable R/M-HNSCC patients at our institution between 1/2008 and 6/2020. The study aimed to evaluate outcomes of early recurrent patients receiving 1L systemic treatment and assess TTRIs and recurrent patterns' impact on survival.
Results
234 of 1,281 eligible patients were included. Platinum-based doublet chemotherapy was the predominant 1L treatment. Significant differences in PFS and OS were observed among TTRI groups. In early recurrent patients, those receiving platinum-based doublet and monotherapy showed significantly longer OS compared to best supportive care (BSC). Locoregional recurrence was the most common pattern (47%), followed by distant metastasis (22%) and both (20%). Different R/M-HNSCC patterns were significantly associated with OS (p=0.019), but not PFS (p=0.790). In multivariate analysis, TTRI of ≥12 months correlated with PFS (HR 0.51; p=0.004) and OS (HR 0.58; p=0.009), while recurrence pattern did not. Table: 931P
TTRI | <6 month (47%) | 6-12 month (22%) | >12 month (20%) | De novo M1 (11%) | p-value |
All PFS (months) | 2.9 | 2.8 | 5.0 | 3.8 | 0.028 |
All OS (months) | 4.1 | 5.1 | 8.8 | 5.3 | 0.006 |
OS of patients with 1L treatment Platinum-doublet Monotherapy BSC | 5.8 4.1 2.5 | 8.4 12.7 2.3 | <0.001 |
Conclusions
In our study, R/M-HNSCC patient survival was significantly influenced by TTRI, while recurrence pattern was not. Despite poor prognosis, early recurrent patients benefited from systemic treatments. TTRI should be a stratification factor in future clinical trials, as varying prognoses were observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Ngamphaiboon: Financial Interests, Personal, Invited Speaker: Roche, MSD, Merck, Eisai; Financial Interests, Personal, Advisory Board: BeiGene, BMS, Roche, MSD, Eisai, Merck; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Principal Investigator: RAPT therapeutics, Boehringer Ingelheim Pharmaceuticals, MSD, Roche, BeiGene, Pfizer; Financial Interests, Institutional, Project Lead: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12